Representative Matters
REFERENZMANDATE
代表事项
Public Offerings
- Orchard Therapeutics in its $225 million initial public offering
- AquaVenture Holdings in its $117 million initial public offering
- Intellia Therapeutics in its $108 million initial public offering
- CRISPR Therapeutics in its $56 million initial public offering and its $200 million follow-on offering
Private Financings
- Moderna Therapeutics in its $110 million Series D financing and $500 million Series E financing
- Intellia Therapeutics in its $15 million Series A financing and $70 million Series B financing
- Nimbus Therapeutics in its $43 million Series B financing and $65 million Series C financing
- Scholar Rock in its $36 million Series B financing and $47 million Series C financing
- Cullinan Oncology in its $150 million Series A financing
- Kymera Therapeutics in its $30 million Series A financing
- Ginkgo Bioworks in its agreement with Bayer to launch JoynBio for $100 million Series A investment
Strategic Collaborations and M&A
- Teva Pharmaceuticals in its $3.2 billion acquisition of Auspex Pharmaceuticals
- Versant Ventures in its strategic transaction with Bayer to form BlueRock Therapeutics, with a combined financing amount of $225 million
- Foundation Medicine in its strategic collaboration with Roche, valued at more than $1 billion, and subsequent $2.2 billion merger with Roche
- Quartet Medicine in its $595 million strategic collaboration with Merck
- Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead, with $400 million upfront and the potential to receive an additional $800 million over time and strategic alliance with Celgene Corporation in immunology
- CRISPR Therapeutics in its collaboration with Bayer, valued up to $335 million upfront
- Padlock Therapeutics in its $225 million sale to Bristol Myers Squibb
- F-star Alpha in its agreement with Bristol-Myers Squibb
- Moderna Therapeutics in its collaboration with AstraZeneca to co-develop and co-commercialize immune-oncology mRNA Therapeutics
- Warp Drive Bio in its acquisition by Revolution Medicines
- Sage Therapeutics in its collaboration with Shionogi for $90 million up front and potential deal value in excess of $575 million
- Pairwise Plants in its collaboration with Monsanto to advance agriculture research and development by leveraging gene editing technology for $100 million
- Alnylam Pharmaceuticals on its strategic restructuring of its RNAi therapeutics alliance with Sanofi
